Searched for
GENERIC MEDICINES
India needs policy predictability to speed up drug approvals and boost pharma innovation: OPPI DGAnil Matai from the Organisation of Pharmaceutical Producers of India emphasized the need for regulatory predictability. He noted that Indi...
Be cautiously optimistic, and focused on the medium term: 5 mid-cap stocks with upside potential of up to 28%As the mood of the market changes, the stance should be the same as what we have been advocating these past few weeks: Cautious optimism. T...
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%That market has seemingly shed the fear that was dominating it these past several months. However, even as a recovery takes place, it is no...
Laurus Labs shares tumble nearly 9% after promoters sell stake worth Rs 500 crore; multibagger stock up 122% in one yearLaurus Labs shares fell nearly 9% after promoters, including founder and CEO Satyanarayana Chava, sold over 20 lakh shares worth Rs 487 cro...
Glenmark launches generic of Inlyta tablets for kidney cancer treatment in USGlenmark Pharmaceuticals Inc has announced the launch of Axitinib Tablets in the United States in two strengths. These tablets are a generi...
For investors with patience and ability to take moderate risk: 5 mid-cap stocks with upside potential of up to 26%For all those who have decided it is now time to turn bullish, here’s a small reminder: The past year has been a very tough one for mid-cap...
18 patent applications for HIV drug lenacapavir may delay affordable generics in IndiaGilead Sciences has filed 18 patent applications in India for lenacapavir, raising concerns among patient groups. They argue these applicat...
Stock picks of the week: 6 stocks with consistent score improvement and upside potential of up to 28% in 1 year, according to analystsIt is not time yet to abandon the discipline that got you through the bad patch which the market has seen in the last over two years. So, g...
India's innovation journey begins in classrooms: Narayana MurthyAdvocating for transformative educational reforms, NR Narayana Murthy suggested a nationwide program to prepare 500,000 teachers annually b...
Pharma & healthcare funds top mutual fund return charts with over 19% gains. Should investors invest now or wait for a correction?Pharma and healthcare mutual funds have topped return charts in 2026 with over 19% gains. While strong sector growth supports the outlook, ...
BDR Pharma to acquire Acme’s oral solid formulations businessBDR Pharma will acquire a controlling stake in Acme Formulation’s oral solid formulations business from existing shareholders, led by priva...
Over 1,300 anti-cancer drugs to get cheaperIndia's National Pharmaceutical Pricing Authority is set to cap trade margins on anti-cancer drugs starting November 2026. The initiative a...
Morepen Laboratories launches Desloratadine (Rx) generic drug product in US marketMorepen Laboratories has launched its prescription generic product Desloratadine in the United States market. This launch is managed throug...
Pharma industry steps up API investments to cut import dependence, move up value chainIndia's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Invest...
Dr Reddy's Laboratories receives ANVISA approval for generic semaglutide injection in BrazilDr Reddy’s Laboratories obtained marketing authorisation from Brazil’s ANVISA for a generic semaglutide injection. The product will be avai...
Sun Pharma’s specialty portfolio, Organon deal to drive growthSun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines....
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
Sun Pharma Q2 profit takes a hit on exceptional itemsSun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue ...
Sun Pharma Q2 profit falls 36% as litigation costs hit earningsSun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Reven...
India’s drug pricing policy must balance affordability, medicine availability and pharma industry growthThe Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussi...